S&P Futures
3,837.50+9.50(+0.25%)Dow Futures
31,367.00-4.00(-0.01%)Nasdaq Futures
12,866.75+35.00(+0.27%)
Enveric Biosciences, Inc. (ENVB)
3.6000 -0.04 (-1.10%)
Pre-Market: 4:21AM EST
Chart Events
Performance Outlook
| Previous Close | 3.8200 |
| Open | 3.9918 |
| Bid | 0.0000 x 4000 |
| Ask | 0.0000 x 2200 |
| Day's Range | 3.5300 - 4.0000 |
| 52 Week Range | 1.4800 - 21.2000 |
| Volume | 1,443,771 |
| Avg. Volume | 1,788,570 |
| Market Cap | 66.744M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 23, 2008 |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has launched a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc. ("PureForm"), a biotechnology company focused on the research, development and commercialization of synthesized CBD and other cannabinoids, for treating pain and inflammation resulting from cancer treatments. The agreement allows two leading edge companies to bring their focus and resources to bear on superior products to serve unmet medical needs.
- PR Newswire
Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock
Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing on February 11, 2021 of its previously announced registered direct offering of 3,007,026 shares of its common stock, at a purchase price of $4.27 per share for gross proceeds of approximately $12,840,000. Enveric has also issued to the investors unregistered warrants to acquire 1,503,513 shares of common stock at $4.90 per share, exercisable immediately and terminating five years after the date of issuance.
- PR Newswire
Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering
Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 3,007,026 shares of Enveric's common stock, at a purchase price of $4.27 per share, in a registered direct offering. Enveric has also agreed to issue to the investors unregistered warrants to acquire 1,503,513 shares of Common Stock at $4.90 per share, exercisable immediately and terminating five years after the date of issuance. The closing of the offering is expected to occur on or about February 11, 2021, subject to the satisfaction of customary closing conditions. Following completion of the offering, the Enveric is expected to have 18,336,367 shares of common stock issued and outstanding.
